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OBJECTIVE—Given the increasing prevalence of both metabolic syndrome (MetS) and de-
pressive symptoms during old age, we aimed to examine prospectively the association between
MetS and the onset of depressive symptoms according to different age-groups in a large, general
elderly population.
RESEARCH DESIGN AND METHODS—This was a prospective cohort study of 4,446
men and women aged 65–91 years who were free of depression or depressive symptoms at
baseline (the Three-City Study, France). MetS was deﬁned using the National Cholesterol Ed-
ucation Program Adult Treatment Panel III criteria. New onset of depressive symptoms (the
Center for Epidemiologic Studies Depression Scale score $16 and use of antidepressant treat-
ment) was assessed at 2- and 4-year follow-ups.
RESULTS—After adjusting for a large range of potential confounders, we observed MetS to be
associated with 1.73-fold (95% CI 1.02–2.95) odds for new-onset depressive symptoms in the
youngestage-group(65–70yearsatbaseline),independentlyofcardiovasculardiseases.Nosuch
association was seen in older age-groups.
CONCLUSIONS—Our ﬁndings suggest that the link between MetS and depressive symp-
toms evidenced until now in middle-aged people can be extended to older adults but not to the
oldest ones. Additional research is needed to examine if a better management of MetS prevents
depressive symptoms in people aged 65–70 years.
Diabetes Care 34:904–909, 2011
A
lthough depression has long been
s h o w nt ob ea s s o c i a t e dw i t ht h e
development of metabolic syn-
drome (MetS) (1), more recent evidence
of a bidirectional association has been re-
ported in young (2) and middle-aged
women (3,4) and older men (5), sug-
gesting a more complex etiological path-
way than has previously been considered.
Werecentlyhaveconﬁrmedtheassociation
between MetS and depressive symptoms
in a larger, middle-aged population (6),
suggesting that better management of
MetSmightreducetheincidenceofdepres-
sive symptoms in those within the age
range of 40–60 years. The adverse conse-
quences of depression on quality of life in
older adults (7), combined with the in-
creasing prevalence of MetS (8) during
o l da g e ,r a i s e di n t e r e s ti ne s t a b l i s h i n g
whether MetS continues to increase the
risk of depressive symptoms in older
people. Any potential association beneﬁts
from a biologically plausible hypothesis.
Research suggests that the etiology of late-
onset depression is linked to vascular cau-
ses, such as diseases of the blood vessels
and circulation (9). There also are clear as-
sociations between diabetes and neuro-
degenerative disease and, within these
diseases,depressionandothermooddisor-
derscanbeanearlyandobservablefeature.
Thus, our objective was to prospectively
assess the association between MetS and
onset of depressive symptoms according
todifferentage-groupsintheelderlybyus-
ing data from a large, general-population
cohort.
RESEARCH DESIGN AND
METHODS—The Three-City Study
(3C study) is an ongoing multisite cohort
study of community-dwelling people
aged $65 years recruited from the elec-
toral rolls of three French cities (Bor-
deaux, Montpellier, and Dijon) from
1999 to 2001 (n = 9,294) (10). Partici-
pants were interviewed by trained staff
and underwent a number of clinical ex-
aminations at baseline and at 2 and 4
years. The study protocol was approved
by the ethics committee of the University
Hospital of Bicêtre (Paris, France), and
written informed consent was obtained
from each participant. Participants with
dementia (n = 500), those who presented
with depressive symptoms (n =2,066),or
those who reported past or current major
depressive disorder episodes (n = 540) at
baseline were excluded. Of these 6,188
participants, the present analyses were
carried out in the 4,446 participants
who had complete data on MetS, had all
covariatesmeasuredatbaseline,and hadat
least one assessment of depressive symp-
toms available at the 4-year follow-up.
Data collection
Assessment of MetS. The MetS was
deﬁned at baseline, using the National
Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III) cri-
teria (11), based on the presence of three
or moreof thefollowing:waist circumfer-
ence:men.102cmandwomen.88cm;
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ORIGINAL ARTICLEserum triglycerides: $1.7 mmol/L; HDL
cholesterol: men ,1.04 mmol/L and
women , 1.29 mmol/L; systolic blood
pressure: $130 mmHg and diastolic
blood pressure 85 mmHg; fasting glu-
cose: $6.1 mmol/L, or presence of type
2 diabetes. As data on the established di-
agnosisoftype2diabetesbyapractitioner
were not available, the use of antidiabetes
treatment was considered as a proxy. De-
tails of procedures regarding waist cir-
cumference, blood pressure, fasting
blood glucose, HDL cholesterol, and tri-
glyceride measurements have been previ-
ously described (12).
Assessment of depression and depres-
sive symptoms at baseline and over the
follow-up. At each wave, depressive
symptomatology was assessed using the
CenterforEpidemiologicStudiesDepres-
sion Scale (CES-D), which has been val-
idated in the general population (13).
Depressive symptomatology refers to
any symptoms of depression reported by
subjects on the CES-D, with the higher
number of symptoms representing
greater severity. A cutoff point of 16 on
the CES-D provides a categorical division
of symptoms, with higher scores corre-
sponding to clinically signiﬁcant levels
of depressive symptomatology warrant-
ing clinical intervention (13). Subjects
with low levels of depressive symptom-
atology are referred to as a low-symptom
group. In longitudinal analyses, incident
depressive symptoms were identiﬁed
from this low-symptom group who were
not treated by antidepressants at baseline
but who subsequently had incident de-
pressive symptoms or began an antide-
pressant treatment during the follow-up.
To strengthen the assumption that partic-
ipants included in the present analyses
were free of depressive symptoms, we
alsoexcludedsubjectswithlifetimemajor
depressive episodes according to the
DSM-IV criteria by using the Mini Inter-
national Neuropsychiatry Interview, a
standardizedpsychiatricexaminationval-
idated in the general population (14).
Assessment of covariates at baseline.
Sociodemographic variables consisted of
sex, age, study center, marital status
(living alone, married, or cohabitating),
and educational level (no formal educa-
tion, primary school or lower secondary
education, or higher secondary education
or university degree). The health behav-
iors considered were smoking status
(nonsmoker, former smoker, or current
smoker) and alcohol consumption (non-
drinker; moderate drinker, deﬁned by
three glasses or less per day for men and
two glasses or less per day for women; or
heavy drinker, deﬁned by three or more
glasses per day for men and two or more
glasses per day for women). Health status
was ascertained using BMI categories
(normal: BMI ,25 kg/m
2,o v e r w e i g h t :
25 # BMI , 30 kg/m2,o b e s e :B M I$30
kg/m
2). Cognitive impairment was de-
ﬁned as having a score ,24 on the
Mini-Mental State Examination (MMSE);
disability was evaluated using the Instru-
mental Activities of Daily Living (IADL)
scale (score .0); treatment of MetS was
determined by the use of lipid-lowering
drugs; and treatment of hypertension was
determined by the use of hypotensor, an-
giotensor, b-blockers, diuretics, and
lipid-lowering drugs. An inventory of all
drugs (prescription and over-the-counter
drugs) used during the preceding month
was included in a standardized interview.
Medical prescriptions and, where feasi-
ble, the medications themselves were
checked by the interviewer. In addition,
self-reported history of cardiovascular or
cerebrovasculardisease(CVD)(anginapec-
toris, myocardial infarction, coronary bal-
loon dilation or artery bypass, stroke, or
peripheral artery disease surgery) at base-
line and incident CVD (including stroke)
over the follow-up also was considered.
Statistical analyses
A Studentt test (for continuous variables)
and the x
2 test (for categorical variables)
were used to compare characteristics of
participants according to 1)t h ep r e s e n c e
of new-onset depression based on the
CES-D and 2) MetS status at baseline. Lo-
gistic regression models were performed
toassesstheassociationbetweenMetS,its
components, and onset of depression
based on the CES-D. The statistically sig-
niﬁcant interaction found between age
and MetS in new-onset depressive symp-
toms (Wald test P = 0.03) led us to con-
ducttheseanalysesseparatelywithineach
age-quartile group. The following were
mean ages (SDs) for each group: age-
group 1: 67.9 (1.04); age-group 2: 71.1
(1.0); age-group 3: 74.7 (1.1); and age-
group 4: 79.9 (2.5). These analyses were
adjusted for age at baseline (by year), sex,
study center, education, marital status,
smoking habits, alcohol consumption,
BMI categories, cognitive impairment,
disability, MetS treatment, and self-reported
historyofCVDatbaseline.Furthermore,to
explore whether any association between
MetS and depression based on the CES-D
could be driven by CVD, we repeated the
analyses after excluding participants who
self-reported a history of CVD at baseline
or who developed incident CVD over the
follow-up. All analyses were conducted
using SAS software (version 9.2; SAS
Institute).
RESULTS—Over the 4-year follow-up,
827 (18.6%) new cases of depression
based on the CES-D were observed. Char-
acteristics of the population as a function
of incident CES-D depressive symptoms
over the 4-year follow-up are detailed
in Table 1. Overall, the prevalence of
MetS was 12.9% (n = 574) at baseline.
Compared with MetS-free participants,
t h o s ew i t hM e t Sw e r em o r el i k e l yt ob e
men (P = 0.002), to be former smokers
(P , 10
24), to be in higher BMI categories
(P , 10
24), to have less education (P =
0.002), to have more disabilities (P =
0 . 0 2 ) ,t oh a v em o r ec o g n i t i v ed e ﬁcits
(P = 0.002), to report a history of CVD
(P = 0.0003), and to developCVD during
the study (P = 0.009) (Supplementary
Table 1).
The results of Table 1 show that the
incidence of depressive symptoms in-
creased signiﬁcantly across age-groups
(P , 0.0001). Table 2 shows the associa-
tion of MetSwith theincidenceof depres-
sive symptoms by age-groups categorized
according to quartile distribution. In age-
group 1 (ﬁrst quartile), participants with
MetS were more likely to develop depres-
sive symptoms (odds ratio 1.73 [95% CI
1.02–2.95]) compared with participants
without MetS at baseline, after adjusting
for a large range of sociodemographic
characteristics (sex, study center, educa-
tional attainment, and marital status),
health behaviors (smoking and alcohol
consumption), and health-status factors
(MetS treatment, cognitive deﬁcit, dis-
ability, BMI, and self-reported history of
CVD at baseline). In older age-groups,
there was no statistically signiﬁcant asso-
ciation between MetS and new onset of
depressive symptoms.
To assess the robustness of this ﬁnd-
ing, we performed analyses in age-groups
thatwerecategorizedapriori(aged65–70
years, n = 1,300; aged 70–75 years, n =
1,558; aged 75–80 years, n = 1,164;
andaged80–91years,n=424).Theseanal-
yses conﬁrmed the main analysis by show-
ingthatMetSwasassociatedwitha1.8-fold
odds ratio for new-onset depressive symp-
toms in elderly subjects aged 65–70 years
(odds ratio 1.82 [95% CI 1.12–2.95]), but
no association was found for older partic-
ipants (Supplementary Table 2).
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Akbaraly and AssociatesThe MetS is deﬁned as a clustering of
ﬁve metabolic disorders, including ele-
vated abdominal obesity, low HDL cho-
lesterol, high triglycerides, high blood
pressure, and high fasting glucose or type
2 diabetes. We performed an analysis to
examine which speciﬁc MetS components
were associated with new onset of depres-
sive symptoms over the 4-year follow-up,
especially in age-group 1. Of ﬁve MetS
components, only the low HDL choles-
terol component was signiﬁcantly as-
sociated with new onset of depressive
symptoms in that age-group.
The evidence of an association be-
t w e e nC V Da n dd e p r e s s i o n( 1 5 ) ,c o m -
b i n e dw i t ht h ef a c tt h a tM e t Si sa n
establish risk factor for CVD (8), led us
to explore whether the association be-
tween the MetS and new-onset depres-
sion would be driven by CVD. Analyses
were rerun after excluding participants
who 1) reported a history of CVD at base-
line (n =666)and2) developed CVD dur-
ing the 4-year follow-up (n = 201). The
age-dependent association was largely
replicated, with MetS retaining its ob-
served association with a higher odds of
new-onset depression in age-group 1, af-
ter excluding participants with a self-
reported history of CVD (odds ratio
1.85 [95% CI 1.04–3.27]) and after addi-
tionally excluding participants with inci-
dent cases of CVD during the follow-up
(odds ratio 2.06 [1.15–3.67]).
CONCLUSIONS—Toourknowledge,
thisistheﬁrststudytoreporttheassociation
between MetS and the onset of depressive
symptoms across different age-groups in a
prospective, multicentric, elderly general-
population cohort. MetS was associated
with an almost doubling of the odds for
new-onsetdepressivesymptomsintheage-
group 65–70 years, even in subjects with-
outapparentCVDpathologies,whereasfor
older age-groups the association was not
signiﬁcant.
Several cross-sectional studies have
shown an association between the MetS
and depression in young adults (16) and
middle-aged populations (17–19). Al-
though in several studies the assumption
has been that depression predicts the
MetS, depression also could be a conse-
quenceoftheMetS.Todate,thisdirection
of the association has been prospectively
investigated in the middle-aged popula-
tion (3,4,6), and a “two-way street” be-
tween depression and the MetS is now
evidenced.Ourobservationofanelevated
risk of developing depressive symptoms
in both pre-elderly men and women with
MetS is consistent with a previous report
(6) carried out in a large, middle-aged
British population that included men
and women. Another prospective study
(3) carried out in the middle-aged popu-
lation has suggested a sex-speciﬁca s s o c i -
ation by ﬁnding an association in women
but not in men and was in accordance
with a previous study (4) reporting an as-
sociation between MetS and depressive
symptoms in a cohort of middle-age
women. The absence of a relationship in
menmay,however,resultfromthelackof
Table 1—Characteristics of 4,446 3C study participants according to the onset of new
CES-D depression cases over the 4-year follow-up
Cumulative onset of depressive symptoms*
No (%) Yes (%) P
n 3,619 827
Age-quartile groups ,10
24
65.0–69.4 26.0 20.8
69.4–72.8 25.6 22.1
72.8–76.8 24.6 26.7
76.8–91.1 23.8 30.3
Sex ,10
24
Men 49.3 27.8
Women 50.7 72.2
Marital status ,10
24
Living alone 29.5 37.0
Married or cohabiting 70.5 63.0
Education ,10
24
No qualiﬁcation/primary 29.6 37.0
Lower secondary 29.6 31.1
Higher secondary or higher 40.9 32.9
Smoking habit ,10
24
Never smoker 57.0 65.1
Former smoker 37.7 30.1
Current smoker 5.3 4.8
Alcohol consumption 0.0004
Nondrinker 16.5 20.2
Moderate 63.2 64.8
Regular 20.3 15.0
BMI categories 0.02
Normal 45.6 49.0
Overweight 42.3 37.1
Obesity 12.1 13.9
Cognitive deﬁcit (MMSE ,24) 0.14
No 96.9 95.9
Yes 3.1 4.1
Use of antihypertensive drugs 0.04
No 56.9 53.1
Yes 43.1 46.9
Use of lipid-lowering drugs 0.21
No 67.9 70.1
Yes 32.1 29.9
Disability (assessed by the IADL scale) ,10
24
No 96.0 92.3
Yes 4.0 7.1
Self-report history of stroke and CVD 0.005
No 85.7 81.9
Yes 14.3 18.1
*OnsetofdepressionbasedontheCES-Doverthe4-yearfollow-upwasdeﬁnedbyreportingincidentCES-D
depression (deﬁned by a CES-D score $16 or use of antidepressive drugs) over the 4-year follow-up, after
excluding participants with prevalent CES-D depression at baseline and those who reported past or actual
major depressives episodes.
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Metabolic syndrome and depression in the elderlystatistical power as a result of the lower
prevalence of MetS combined with the
lower incidence of depressive symptoms
i nm e nc o m p a r e dw i t hw o m e n .I no u r
study, no evidence of an interaction
with sex was found in the MetS/depres-
sive symptoms relationship. Our results
areinlinewiththosereportedbyAlmeida
et al. (5), which was a study carried out
on a large cohort of Australian older men
(12,216 men aged 65–84 years), indicat-
ing that MetS was associated with an in-
crease in the risk of incident depression.
MetS has gained clinical currency as a
robust predictor of cardiovascular mor-
bidity (8), which may consequently raise
the prevalence of “vascular depression”
(9). It is therefore crucial to determine
whether the association between the
MetS and depressive symptoms is not
drivenbydepressivesymptomsgenerated
bymanifestCVD.Toourknowledge,very
few studies have investigated this ques-
tion (20). The present data provide evi-
dence that the observed MetS/depression
association may be independent of past,
current, and incident CVDs and thus
constitutes a novel ﬁnding.
Regarding the speciﬁc components of
MetS, our data showed that the low HDL
cholesterol component was associated
with increased odds of new-onset depres-
sivesymptomsinthoseaged65–70years.
Corresponding associations in that age-
group were not observed for other MetS
components. These data are in agreement
with recent ﬁndings on the importance of
dyslipidemia in the etiology of late-life
depression (21) and also may imply that
the association observed between MetS
and depressive symptoms may be par-
tially driven by HDL cholesterol in the
pre-elderly participants. Additional
work is needed to assess whether a better
management of HDL cholesterol would
reduce the incidence of depressive symp-
toms in this age-group.
The reason why MetS would predict
new-onsetdepressive symptoms untilage
70 years but not after remains unclear.
MetS, asan entity,isan empiricalconcept
(8),anditispossiblethatitsclinicalutility
is less relevant in late-elderly subjects
than in young elders. Another explana-
tion would be that the MetS/depression
relationship in older-aged subjects is
masked by the higher disability, morbid-
ity, and mortality rate associated with
older age, because poor health is associ-
ated with both the MetS (12) and late-
onset depression (14) in our previous
work carried out in the 3C study and
other cohorts. Finally, our results also
Table 2—Association of MetS and each of its components with onset of depressive symptoms over the 4-year follow-up by age-quartile group
Age-groups
Without MetS or
components
[n (% depressed)]
With MetS or
components,
[n (% depressed)]
Odds ratio
(95% CI)* P
Overall MetS
65.0–69.4 989 (14.8) 123 (21.1) 1.73 (1.02–2.95) 0.04
69.4–72.8 963 (16.4) 148 (16.9) 1.18 (0.70– 1.97) 0.58
72.8–76.8 960 (19.8) 152 (20.4) 0.94 (0.57–1.52) 0.81
76.8–91.1 960 (22.9) 151 (20.5) 0.89 (0.56–1.42) 0.63
Central obesity component†
65.0–69.4 863 (14.6) 249 (18.5) 1.18 (0.80–1.75)† 0.40
69.4–72.8 821 (16.0) 290 (17.9) 1.00 (0.68–1.46)† 0.99
72.8–76.8 801 (19.5) 311 (20.9) 0.98 (0.69–1.38)† 0.91
76.8–91.1 770 (22.5) 341 (22.9) 0.86 (0.62–1.19)† 0.37
High triglyceride component
65.0–69.4 933 (15.4) 179 (15.6) 1.14 (0.71–1.84) 0.58
69.4–72.8 916 (16.5) 195 (16.4) 1.11 (0.71–1.74) 0.63
72.8–76.8 947 (19.4) 165 (22.4) 1.18 (0.77–1.80) 0.45
76.8–91.1 943 (22.7) 168 (22.0) 0.99 (0.65–1.50) 0.95
Low HDL cholesterol component
65.0–69.4 1,025 (14.8) 87 (23.0) 1.81 (1.04–3.17) 0.03
69.4–72.8 998 (16.5) 113 (15.9) 1.03 (0.59–1.80) 0.91
72.8–76.8 1,009 (19.4) 103 (24.3) 1.23 (0.74–2.03) 0.42
76.8–91.1 1,021 (22.1) 90 (27.8) 1.37 (0.82–2.29) 0.22
Hypertension component
65.0–69.4 274 (18.6) 838 (14.4) 0.88 (0.60–1.30) 0.53
69.4–72.8 229 (21.8) 882 (15.1) 0.70 (0.47–1.03) 0.07
72.8–76.8 193 (26.9) 919 (18.4) 0.63 (0.43–0.92) 0.02
76.8–91.1 175 (25.7) 936 (22.0) 0.91 (0.61–1.33) 0.62
High fasting blood glucose component
65.0–69.4 991 (15.3) 121 (16.5) 1.25 (0.70– 2.21) 0.45
69.4–72.8 982 (15.8) 129 (21.7) 1.80 (1.10– 2.96) 0.02
72.8–76.8 973 (20.1) 139 (18.0) 0.88 (0.54– 1.45) 0.63
*Odds ratio adjusted for age at baseline (by year), sex, study center, MetS treatment (use of lipid-lowering drugs or antihypertensive drugs), educational attainment,
marital status, smoking, alcohol consumption, cognitive deﬁcit (MMSE ,24), disability (assessed by the IADL scale), BMI, and self-reported history of CVD (in-
cludingstroke) atbaseline. The reference (oddsratio =1)corresponded tothesubjectswithout MetS(orMetScomponents) for eachage-groupandconditions. †BMI
categories were not included in this model.
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Akbaraly and Associatesmay reﬂect the fact that the late onset of
late-lifedepression(afterage70years)did
notsharethesameetiology,andtherefore
the same risk factors, as the onset of de-
pressive symptoms in middle-aged and
pre- and “young”elderly subjects (7). Addi-
tional work is needed to further investigate
whether the MetS/depressive symptoms
relationship is different before and after
age 70 years.
The longitudinal and multicentric
design and the large sample size, which
included.4,000elderlysubjectsfromthe
general population, constitute the major
strengths of this investigation. Further-
more, to strengthen the assumption that
participants included in the present anal-
yses are free of depressive symptoms, we
made the choice to also exclude all partic-
ipants who were diagnosed at baseline as
having current or past major depressive
episodes based on the MINI Psychiatric
Interview, which was administered in the
entire 3C study cohort only at baseline.
The limitations of the present report in-
cluded, ﬁrst, the classiﬁcation of the clin-
ical level of depression using the CES-D.
This instrument has, however, been vali-
dated in the elderly general population,
with a cutoff point of 16, which corre-
spondstoclinicallysigniﬁcantlevelsofde-
pressive symptomatology and warrants
clinical intervention (13). A second draw-
back involves reliance on the NCEP-ATP
III in deﬁning MetS, whereas other deﬁni-
tions also exist (8). However, the NCEP-
ATP III is the most widely used deﬁnition,
thus allowing us to compare our results
withotherstudies.Furthermore,asthedi-
agnosis of type 2 diabetes by a general
practitioner was not assessed in the 3C
study at baseline, we considered partici-
pantswhoreportedtheuseofantidiabetes
drugs as having type 2 diabetes to com-
pute MetS according to NCEP-ATP III cri-
teria. Third, the design of our study, an
observational epidemiological study with
MetS only assessed at baseline, does not
permitustoconcludethatthereisacausal
link between MetS and depressive symp-
toms. Furthermore, the description of fac-
tors associated with the MetS condition
suggests that participants with MetS at
baseline constitute a vulnerable popula-
tion and thus the possibility that unmea-
sured confounders may partly explain the
observed associations remains. However,
our results were robust to adjustments
for a large range of sociodemographic,
health behavior, and health status factors,
making it less probable that they were at-
tributable to confounding or obtained by
chance.Additionalinvestigationisneeded
to establish MetS as an etiological factor
for depression in pre-elderly subjects; es-
pecially, it remains to be shown whether a
better management of MetS or its rever-
sion is associated with lower incidence of
depressive symptoms.
Despite these limitations, by explor-
ing MetS/depressive symptoms across
different age-groups in the elderly, our
ﬁndings suggest that the MetS/depressive
symptoms link evidenced until now in
middle-aged subjects can probably be
extended to young elderly populations
but not to the oldest ones. At this stage, it
is too early to present MetS as a predictor
of depression, but under the hypothesis
that prevention and treatment of MetS
may be important for the prevention of
depressive symptoms in middle age (6),
results of our study would suggest that
such intervention studies also would be
justiﬁed in order to prevent depressive
symptoms in populations between 65
and 70 years of age.
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